{
  "ticker": "ECS",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02966551",
  "id": "02966551",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250707",
  "time": "0921",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250707/pdf/06ljll71wkl4nj.pdf",
  "summary": "- **Clinical Trial Support**: ECS to supply Avani THC10 Softgel Capsules for a University of Western Australia clinical trial on medicinal cannabis for obstructive sleep apnoea (OSA).  \n- **Trial Details**: Double-blind study targeting 24 participants, assessing 10mg THC\u2019s impact on OSA severity and cognitive performance; recruitment starts July 2025.  \n- **Strategic Focus**: Reinforces ECS\u2019s commitment to clinical validation of medicinal cannabis, though no immediate financial/material impact disclosed.  \n\n*No material trading or capital markets-specific information identified.*",
  "usage": {
    "prompt_tokens": 964,
    "completion_tokens": 117,
    "total_tokens": 1081,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-06T23:32:45.515116"
}